Unicycive Therapeutics, Inc. (UNCY)
$4.11+0.98%Close
SELLCRISIS · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $110M
- Beta
- 1.78
- P/E (TTM)
- -2.53
- Short % float
- 19.99%
- Days to cover
- 5.7
- SI change
- +15.5%
- 1W
- -2.61%
- 1M
- -22.60%
- vs SPY 1W
- -3.77%
- vs SPY 1M
- -25.59%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on UNCY?
- LOPJLB’s latest quantitative signal on Unicycive Therapeutics, Inc. (UNCY) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is UNCY in?
- Unicycive Therapeutics, Inc. (UNCY) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Unicycive Therapeutics, Inc. (UNCY) do?
- Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.